Frevecitinib

Overview

Frevecitinib (KN-002) is a potent pan- JAK inhibitor (i.e. JAK1 , JAK2 , JAK3 , TYK2 ). Frevecitinib can be used for the study of asthma and other respiratory conditions such as chronic obstructive pulmonary disease (COPD).

Application

Products | Products > Disease Areas > Respiratory Inflammation | Products > Disease Areas > Asthma | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Lower Respiratory Inflammation | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > JAK/STAT Signaling | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > JAK

Product Information

• Catalog No.: HY-159536
• CAS No.: 1299417-07-4
• Molecular Formula: C22H21N7O2
• Molecular Weight: 415.45
• Purity: 99.42%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (6.02 mM); Clear solution
• Availability: In-stock

Source

Original product source